Retrospective analyses of clinical features and therapeutic outcomes in thymectomized patients with myasthenia gravis at Shinshu University

Internal Medicine

Volumn 43, Issue 3, 2004, Pages 189-193

  Dohi Iijima, Naoko ^a   Sekijima, Yoshiki ^a   Nakamura, Akinori ^a   Morita, Hiroshi ^a   Matsuda, Masayuki ^a   Haniuda, Masayuki ^a   Hashimoto, Takao ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aging; Corticosteroid; Thymectomy

Indexed keywords

CHOLINESTERASE INHIBITOR; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; AGED; AGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GROUPS BY AGE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; ONSET AGE; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; RATING SCALE; RELIABILITY; RETROSPECTIVE STUDY; REVIEW; SAFETY; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; THYMECTOMY; THYMOMA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGE FACTORS; HUMANS; MIDDLE AGED; MYASTHENIA GRAVIS; RETROSPECTIVE STUDIES; THYMECTOMY; THYMUS GLAND; TREATMENT OUTCOME;

EID: 1842845010     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.189     Document Type: Review

References (31)

1. Drachman DB. Myasthenia gravis. N Engl J Med 330: 1797-1810, 1994.
2. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 377: 652-669, 1981.
3. Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 65: 492-496, 1998.
4. Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42: 1888-1893, 1992.
5. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 47: 1233-1238, 1996.
6. Christensen PB, Jensen TS, Tsiropoulos I, et al. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology 43: 1779-1783, 1993.
7. Schon F, Drayson M, Thompson RA. Myasthenia gravis and elderly people. Age Ageing 25: 56-58, 1996.
8. Olanow CW, Wechsler AS, Sirotkin-Roses M, Stajich J, Roses AD. Thymectomy as a primary therapy in myasthenia gravis. Ann NY Acad Sci 505: 595-606, 1987.
9. Keesey J. A treatment algorithm for autoimmune myasthenia gravis in adults. Ann NY Acad Sci 841: 753-768, 1998.
10. Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 40: 1828-1829, 1990.
11. Sanders DB, Scoppetta C. The treatment of patients with myasthenia gravis. Neurol Clin 12: 343-368, 1994.
12. Olanow CW, Lane RJM, Roses AD. Thymectomy in late-onset myasthenia gravis. Arch Neurol 39: 82-83, 1982.
13. Monden Y, Nakahara K, Fujii Y, et al. Myasthenia gravis in elderly patients. Ann Thorac Surg 39: 433-436, 1985.
14. Bulkley GB, Bass KN, Stephenson GR, et al. Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg 226: 324-334, 1997.
15. Matsuzaki Y, Tomita M, Onitsuka T, Shibata K. Influence of age on extended thymectomy as a treatment for myasthenia gravis. Ann Thorac Cardiovasc Surg 4: 192-195, 1998.
16. Tsuchida M, Yamato Y, Souma T, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 67: 1563-1567, 1999.
17. Stern LE, Nussbaum MS, Quinlan JG, Fischer JE. Long-term evaluation of extended thymectomy with anterior mediastinal dissection for myasthenia gravis. Surgery 130: 774-778, 2001.
18. Abt PL, Patel HJ, Marsh A, Schwartz SI. Analysis of thymectomy for myasthenia gravis in older patients: a 20-year single institution experience. J Am Coll Surg 192: 459-464, 2001.
19. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38: 497-537, 1971.
20. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52: 629-632, 1999.
21. Aster J, Kumar U. White cells, lymph nodes, spleen, and thymus. in: Pathologic Basis of Disease. 6th ed. Cotran RS, Kumar U, Collins T, Eds. Saunders, Philadelphia, 1999: 644-695.
22. Oosterhuis HJGH. Diagnosis and deferential diagnosis. in: de Baets MH, Oosterhuis HJGH, Eds. Myasthenia Gravis. CRC Press, Boca Raton, 1994.
23. Hokkanen E. Epidemiology of myasthenia gravis in Finland. J Neurol Sci 9: 463-478, 1969.
24. Antonini G, Morino S, Gragnani F, Fiorelli M. Myasthenia gravis in the elderly: a hospital based study. Acta Neurol Scand 93: 260-262, 1996.
25. Sorensen TT, Holm EB. Myasthenia gravis in the country of Viborg, Denmark. Eur Neurol 29: 177-179, 1989.
26. Chiu HC, Vincent A, Newsom-Davis J, Hsieh KH, Hung TP. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 37: 1854-1857, 1987 (published erratum appears in Neurology 38: 1504, 1988).
27. Newsom-Davis J, Vincent A, Willcox N. Acethylcholine receptor antibody: clinical and experimental aspects. in: Receptors, Antibodies and Disease: Chiba Foundation Symposium 90: London, England: Pitman Books Ltd. 1982: 225-247.
28. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Anti-acethylcholine receptor antibodies in myasthenia gravis. Part I, relation to clinical parameters in 250 patients. J Neurol Sci 58: 357-370, 1983.
29. Aarli JA. Late onset myasthenia gravis: a changing scene. Arch Neurol 56: 25-27, 1999.
30. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103: 579-601, 1980.
31. Eimoto T, Kusano T, Ando K, Kikuchi M, Shirakusa T, Kawanami S. Nonneoplastic and nonhyperplastic thymus in myasthenia gravis. An immunohistochemical study with double immunoenzymatic labeling of basement membrane and cellular components. Am J Clin Pathol 94: 36-43, 1990.